A method for quantitative detection of bacteria and drug sensitivity test using microfluidic chip

By designing a microfluidic chip combined with microbeads and a "Christmas tree"-type concentration gradient generator, bacteria and drug sensitivity experiments are implemented simultaneously, solving the problems of time-consuming and expensive equipment in the existing technology, and improving detection efficiency and accuracy .

CN110542757BInactive Publication Date: 2024-12-03QIQIHAR MEDICAL UNIVERSITY
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN201910906456.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2019-09-24
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing microfluidic chips can only implement bacterial or drug sensitivity experiments alone, and cannot perform bacterial detection and drug sensitivity experiments at the same time. The traditional methods are time-consuming, cumbersome, and the equipment is expensive.

Method used

A microfluidic chip was designed to combine microbeads to detect bacteria through antigen-antibody reaction, and to realize drug sensitivity detection in the "Christmas tree"-type concentration gradient generator. The detection accuracy and efficiency are improved through the design of microcradles and microbeads. Antibody-coated microbeads and sterile filter paper sheets were subjected to bacterial and drug sensitivity experiments.

Benefits of technology

The quantitative detection of bacteria and drug sensitivity experiments are achieved simultaneously, which shortens the detection time, improves detection sensitivity and specificity, simplifies the operation steps, reduces the dosage of drug sensitivity reagents, and uses a portable thermostat for cultivation, which significantly improves the experimental efficiency. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN110542757B_ABST
    Figure CN110542757B_ABST
Patent Text Reader

Abstract

The present invention provides a microfluidic chip with a novel structure, and a method for quantitatively detecting bacteria using glass microbeads of a microfluidic chip. The microfluidic chip of the present invention comprises a top layer, a middle layer and a bottom layer structure, wherein the middle layer structure comprises four regions: an inlet region, a detection region, a concentration gradient generator and a waste liquid hole, wherein the inlet region is located between the detection region and the drug sensitivity reaction pool, and at the same time, the present invention fills glass microbeads into the detection region of the microfluidic chip, adopts antigen-antibody technology to quantitatively detect bacteria, and simultaneously performs drug sensitivity detection. The microfluidic chip of the present invention can realize rapid and accurate detection of bacteria, with high sensitivity and high specificity, and at the same time, a small amount of drug sensitivity reagent is used.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of microbial detection, and in particular to a method for quantitatively detecting bacteria and conducting drug sensitivity tests using a microfluidic chip. Background Art

[0002] The traditional gold standard method for bacterial identification is to use culture, which is accurate but time-consuming, cumbersome to operate, and expensive to use with large instruments. The dilution method drug sensitivity test can be used to quantitatively test the in vitro activity of antibiotics against a certain bacterium, which is divided into agar dilution method and broth dilution method. During the experiment, the concentration of the antibiotic is usually diluted in multiples, and the lowest drug concentration that can inhibit the visible growth of the test bacteria is called the minimum inhibitory concentration (MIC). The test concentration range of a specific antibiotic should include the concentration that can detect the interpretive breakpoints (sensitive, intermediate and resistant) of bacteria, and should also include the MIC of the quality control reference strain. Factors affecting drug sensitivity results include culture medium and drug concentration. The culture medium should be prepared according to the nutritional needs of the test bacteria. At the same time, the concentration and total amount of the drug directly affect the results of the antibacterial test and need to be accurately prepared. Commercial drugs should be prepared strictly according to their recommended therapeutic doses.

[0003] Microfluidics is a new technology that has emerged in recent years. Applying it to bacterial detection and drug sensitivity tests can greatly shorten the detection time, reduce consumables, and make the detection equipment small and convenient. Parallel flow type concentration gradient generators are more common. They use the principle of laminar flow to transfer mass through diffusion between parallel adjacent liquid flows to form a concentration gradient perpendicular to the direction of the liquid flow. The characteristics of the gradient formation (such as shape, concentration, interval, etc.) are only related to the type of substance, flow rate and contact time. Common parallel flow type concentration gradient generators include T configuration, Christmas tree configuration, universal type, etc. The "Christmas tree" configuration made using the same principle has a more complex structure. The initial liquid flows undergo multiple diversions and confluences to form a more refined and discontinuous combined gradient. Moreover, it separates the gradient forming device from the reaction analysis area, expanding the area of ​​the analysis area. However, the current microfluidic chip structure can only realize the drug sensitivity test of bacteria alone, and cannot realize the detection of pathogens and their drug sensitivity tests at the same time. Summary of the invention

[0004] In order to solve the above technical problems, the present invention provides a method for quantitatively detecting bacteria using a microfluidic chip combined with microbeads, wherein microbeads coated with antibodies are filled into the microfluidic chip, bacteria are detected using antigen-antibody reaction, and drug sensitivity testing is performed simultaneously.

[0005] In a first aspect, the present invention provides a microfluidic chip, the microfluidic chip comprising a top layer, a middle layer and a bottom layer, wherein the middle layer is a PDMS structure, the bottom layer is a glass slide, the middle layer comprises four regions: an inlet region, a detection region, a concentration gradient generator and a waste liquid well, and the inlet region is located between the detection region and the concentration gradient generator, the concentration gradient generator is a "Christmas tree" type, and comprises n(n+3) / 2 drug sensitivity culture pools, wherein n is equal to 1, 2, 3, 4...;

[0006] Optionally, the inlet area includes a sample loading hole, a diluent / buffer loading hole and a drug loading hole, and the bottom layer of the inlet area is 2-4 μm higher than the bottom layers of other areas to facilitate fast and convenient loading of samples under the action of gravity.

[0007] Optionally, the sample loading hole to be tested is provided with a detachable PVDF membrane with a thickness of 90-110 μm on one side of the concentration gradient generator. During bacterial liquid detection, it prevents the bacterial liquid from flowing into the concentration gradient generator. During drug sensitivity testing, it can be pulled out to form a bacterial liquid flow channel and flow into the concentration gradient generator.

[0008] Optionally, the diameter of the drug sensitivity culture pool is 2-5 mm, and the diameter of the waste liquid hole is 0.5-1 mm.

[0009] Optionally, the detection area includes a micro-tray and micro-beads; the micro-tray is V-shaped or semicircular, the diameter of the micro-beads is 60-90 μm, and the micro-tray is slightly wider than the micro-beads to hold up the micro-beads.

[0010] Optionally, the waste liquid hole includes a detection zone waste liquid hole 1 and a concentration gradient generator waste liquid hole 9, the detection zone waste liquid hole 1 is connected to the detection zone through a liquid channel, and the concentration gradient generator waste liquid hole 9 is connected to the downstream of the drug sensitivity culture tank through a liquid channel.

[0011] Optionally, a curved channel 10 is provided between the inlet area and the concentration gradient generator and between each drug sensitivity culture pool, and the width of the channel between the detection area and the detection area waste liquid hole 1 is 40 μ m, all other channels have a width of 100 μ m.

[0012] In a second aspect, the present invention provides a method for preparing the microfluidic chip, comprising: first sealing the middle layer of the microfluidic chip with the bottom layer of the microfluidic chip, then placing sterile filter paper sheets in the drug sensitivity culture pools respectively, and after plasma treatment, sealing the middle layer of the microfluidic chip with the top layer of the microfluidic chip.

[0013] Optionally, before sealing, each layer of the microfluidic chip is baked at 90° C. for 2 h and irradiated with ultraviolet light overnight.

[0014] In a third aspect, the present invention also provides an application of a microfluidic chip in pathogen identification and drug sensitivity testing, comprising the following steps:

[0015] Step S1: After each layer of the chip is sterilized by high pressure, the bottom layer is sealed with the middle layer, the culture medium is added to the drug sensitivity culture pool, and then a sterile filter paper is added to the drug sensitivity culture pool, and the upper layer is sealed. The sealed complete chip is stored in a refrigerator at 4°C, and the chip surface is irradiated with ultraviolet light for 30 minutes before use;

[0016] Step S2: prepare antibody-coated microbeads, and pump them into the detection area from the sample loading hole to be tested. After the microbeads enter the detection area, use PBS to rinse and pressurize to ensure that there is a microbead on each microtray. Add the bacteria to be tested from the sample loading hole to be tested in the inlet area to the detection area so that the bacterial solution is captured by the microbeads. Use PBS to rinse the excess bacterial solution, and suck out the excess bacterial solution from the waste liquid hole 1 in the detection area. According to the test bacteria, add the corresponding rabbit primary antibody working solution and FITC-labeled goat anti-rabbit fluorescent secondary antibody working solution. After the reaction is completed, use PBS to rinse the excess unreacted liquid, and suck out the excess liquid from the waste liquid hole 1 in the detection area. Observe the chip detection area under a fluorescence microscope, analyze the average fluorescence color concentration of the observation results using Image Pro software, and judge the concentration of the bacteria to be tested according to the standard curve. During the whole process, the chip is placed in a portable incubator for incubation. The size of the portable incubator is 50×30×30cm.

[0017] Step S3: If the fluorescence reaction in the detection area is negative, it proves that the detection result of the bacteria is negative, and the drug sensitivity test is not performed; if the fluorescence reaction in the detection area is positive, the drug sensitivity test is continued.

[0018] Furthermore, the drug sensitivity test in step S3 includes:

[0019] Step S31: flush the liquid channel with PBS, pump the drug into the drug injection hole, pump the diluent into the diluent / buffer injection hole, form drugs with different concentration gradients in each column of holes through the concentration gradient generator, and remove the excess drug solution flowing out of the waste liquid hole 9 of the concentration gradient generator after the sterile filter paper in the drug sensitivity culture pool is completely infiltrated with the drug;

[0020] Step S32: Pull out the PVDF membrane on one side of the sample loading hole to be tested, and add the bacterial solution confirmed to contain pathogens in step S2 to the sample loading hole to be tested. After the bacterial solution fills all the drug sensitivity culture pools, remove the excess bacterial solution flowing out of the waste liquid hole 9 of the concentration gradient generator, and place the chip in a portable incubator for culture. The size of the portable incubator is 50×30×30 cm, and the minimum inhibitory concentration MIC is determined according to the color depth.

[0021] Furthermore, the standard curve in step S2 is drawn by taking 0.5 MCF concentration as equivalent to 1.5×10 8 cfu / mL Escherichia coli was used as a reference, and 1.5×10 8 cfu / mL, 1.5×10 7 cfu / mL, 1.5×10 6 cfu / mL,1.5×10 5 cfu / mL, 1.5×10 4 cfu / mL, 1.5×10 3 cfu / mL, 1.5×10 2 cfu / mL, 1.5×10 1 Cfu / mL concentration of bacterial solution was added to the detection area respectively. After passing through the detection area, the excess unreacted bacterial solution was washed away and observed using a fluorescence microscope. The observation results were analyzed using Image Pro software to analyze the average fluorescence color concentration and draw a standard curve.

[0022] Furthermore, in step S2, the method for preparing the antibody-coated microbeads comprises the following steps:

[0023] Treatment of microbeads: 10 mg of glass microbeads were accurately weighed, soaked in Piranha solution overnight, washed 5 times with sterile ultrapure water, dried at 70 °C for 30 min, added with 2% APTES acetone solution for 1 min, and washed 5 times with acetone and sterile ultrapure water in sequence;

[0024] Preparation of antibody working solution: 1 mg mL in 10 µL -1 Add 50 µL MES buffer and 8 µL 4 mg mL -1 EDC (about 2mmol·mL -1 ) and 12 µL 4 mg mL -1 NHS (about 2mmol·mL -1 ), reacted at room temperature for 15 min, and then added 120 μL 0.1 mol·L -1 PBS buffer was used to terminate the NHS-antibody activated ester formation reaction, and the antibody concentration was 50 µg mL -1 of antibody reaction fluid.

[0025] Bead-coated antibody: Add treated glass beads to the antibody reaction solution and react at room temperature for 2 hours. After the reaction is complete, add 0.1 mol·L -1 The beads were washed with PBS three times to obtain antibody-modified immune microbeads, which were then stored at 4°C for later use.

[0026] The present invention has the following beneficial effects compared with the prior art:

[0027] 1. The microfluidic chip of the present invention can realize the simultaneous quantitative detection of bacteria and drug sensitivity test. At the same time, MIC can be observed in any column of the concentration gradient generator, which is more convenient and faster than traditional methods or other microfluidic drug sensitivity test methods.

[0028] 2. The microfluidic chip detection area of ​​the present invention uses the method of antigen-antibody reaction to achieve rapid and accurate detection of bacteria, with high sensitivity and specificity, simple detection steps, and uses a plasma pump to drive, avoiding manual operation. The amount of drug sensitivity reagent used is small, and the optical density collector used determines the MIC based on the change in color depth, which is fast and effective.

[0029] 3. Compared with the traditional concentration gradient generator drug sensitivity test, the application of paper-based technology in drug sensitivity test in microfluidic chip not only shortens the detection time, improves the detection sensitivity, simplifies the operation steps, but also realizes automatic control, which is more conducive to the observation of experimental results. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 Schematic diagram of the overall structure of the microfluidic chip of the present invention

[0031] Among them, 1-detection area waste liquid hole, 2-detection area, 3-microbeads, 4-microtray, 5-drug loading hole, 6-test sample loading hole, 7-dilution / buffer loading hole, 8-concentration gradient generator, 9-concentration gradient generator waste liquid hole, 10-curve channel.

[0032] Figure 2 Schematic diagram of a portable constant temperature box used in the detection of the present invention.

[0033] Figure 3 It is a standard curve diagram of the detection area of ​​the microfluidic chip of the present invention.

[0034] Figure 4 It is the concentration ratio in the final concentration drug sensitivity culture pool of the concentration gradient generator of the present invention.

[0035] Figure 5 It is the color intensity of different concentration gradients in the drug sensitivity test of the present invention. DETAILED DESCRIPTION

[0036] The embodiments of the technical solution of the present invention are described in detail below. The following embodiments are only used to more clearly illustrate the technical solution of the present invention, and are therefore only used as examples, and cannot be used to limit the scope of protection of the present invention. It should be noted that, unless otherwise specified, the technical terms or scientific terms used in this application should be the usual meanings understood by those skilled in the art to which the present invention belongs.

[0037] Example 1

[0038] See the attached Figure 1 As shown in the figure, the microfluidic chip includes a top layer, a middle layer and a bottom layer structure, wherein the middle layer is a PDMS structure, the bottom layer is a glass slide, and the middle layer structure includes four areas: an inlet area, a detection area 2, a concentration gradient generator 8, and a detection area waste liquid hole 1, a concentration gradient generator waste liquid hole 9, and the inlet area is located between the detection area 2 and the concentration gradient generator 8. The concentration gradient generator 8 is a "Christmas tree" type and includes n(n+3) / 2 drug sensitivity culture pools, where n is equal to 1, 2, 3, 4...

[0039] The inlet area includes a sample loading hole 6, a diluent loading hole 7 and a drug loading hole 5; the diameter of the drug sensitivity culture pool is 2-5 mm, the diameter of the waste liquid hole is 0.5-1 mm, a curved channel 10 is provided between the inlet area and the concentration gradient generator and between each drug sensitivity culture pool, the channel width between the detection area and the detection area waste liquid hole 1 is 40 μm, and the width of all other channels is 100 μm. The bottom layer of the inlet area is 2-4 μm higher than the bottom layers of other areas.

[0040] The detection area 2 includes a micro-tray 4 and micro-beads 3; the micro-tray is V-shaped or semicircular, the diameter of the micro-beads is 50-90 μm, the micro-tray is slightly wider than the micro-beads, and the micro-beads are lifted. The waste liquid hole includes a detection area waste liquid hole 1 and a concentration gradient generator waste liquid hole 9, the detection area waste liquid hole 1 is connected to the detection area through a liquid channel, and the concentration gradient generator waste liquid hole 9 is connected to the downstream of the drug sensitivity culture tank through a liquid channel.

[0041] Example 2

[0042] The preparation method of the microfluidic chip includes: plasma treating the middle layer and the bottom layer of the microfluidic chip, then sealing the middle layer of the microfluidic chip with the bottom layer of the microfluidic chip, then placing sterile filter paper sheets in the drug sensitivity culture pools, and then sealing the middle layer of the microfluidic chip with the top layer of the microfluidic chip. The microfluidic chip is sealed under sterile conditions, and before sealing, each layer of the chip is baked at 90°C for 2 hours and irradiated with ultraviolet light overnight. This embodiment uses soft etching technology to process microfluidic chips.

[0043] Example 3

[0044] Treatment of microbeads: 10 mg of glass microbeads were accurately weighed, soaked in Piranha solution overnight, washed 5 times with sterile ultrapure water, dried at 70 °C for 30 min, added with 2% APTES acetone solution for 1 min, and washed 5 times with acetone and sterile ultrapure water in sequence;

[0045] Preparation of antibody working solution: 1 mg mL in 10 µL -1Add 50 µL MES buffer and 8 µL 4 mg mL -1 EDC (~2mmol·mL -1 ) and 12 µL 4 mg mL -1 NHS (~2mmol·mL -1 ), reacted at room temperature for 15 min, and then added 120 μL 0.1 mol·L -1 PBS buffer was used to terminate the NHS-antibody activated ester formation reaction, and the antibody concentration was 50 μg mL -1 of antibody reaction fluid.

[0046] Bead-coated antibody: Add treated glass beads to the antibody reaction solution and react at room temperature for 2 hours. After the reaction is complete, add 0.1 mol·L -1 The beads were washed with PBS three times to obtain the anti-antibody-modified immune microbeads, which were placed at 4°C for future use.

[0047] The detection channel was cleaned and blocked with 1% bovine serum albumin (BSA) for 15 min. The antibody-coated microbeads were injected into the microchannel at a rate of 10 µL / min using a microinjection pump. -1 The flow rate positive pressure drives the sample injection hole 6 in the inlet area to be pumped into the detection area 2. After the beads enter the detection area, PBS is used to rinse and pressurize to ensure that the beads are spread flat in the detection area. The bacterial solution to be tested is added to the sample injection hole 6 to be tested. The corresponding rabbit primary antibody working solution and FITC-labeled goat anti-rabbit fluorescent secondary antibody working solution are added according to the detected bacteria. After the reaction is completed, PBS is used to rinse the excess unreacted liquid, and the excess liquid is sucked out from the waste liquid hole 1 in the detection area. The chip detection area is observed under a fluorescence microscope, and the average fluorescence color concentration of the observation results is analyzed by Image Pro software. According to the standard curve, the concentration of the bacteria to be tested is determined; the chip is placed in a portable incubator for incubation. The size of the portable incubator is 50×30×30cm (see the attached figure) Figure 2 ) is carried out in

[0048] The method of drawing the standard curve is as follows: first, add samples with known bacterial concentrations, and then use different bacterial concentrations, with 0.5 MCF concentration equivalent to 1.5 × 10 8 cfu / mL Escherichia coli was used as a reference, and 1.5×10 8 cfu / mL, 1.5×10 7 cfu / mL, 1.5×10 6 cfu / mL, 1.5×10 5 cfu / mL, 1.5×10 4 cfu / mL, 1.5×10 3 cfu / mL, 1.5×10 2cfu / mL, 1.5×10 cfu / mL bacterial solution were added to the detection area respectively. After passing through the detection area, the excess unreacted bacterial solution was washed away and observed using a fluorescence microscope. The observation results were analyzed using Image Pro software to analyze the average fluorescence color concentration. The same concentration of bacterial solution was tested three times, and the bacterial concentration was used as the horizontal axis and the average fluorescence color concentration as the vertical axis to draw a standard curve (see Figure 2). Figure 3 ).

[0049] Example 4

[0050] According to the method of Example 3, a bacterial solution with a certain concentration of bacteria present is confirmed by fluorescence microscopy, and a drug sensitivity test is performed. During the drug sensitivity test, the PVDF membrane on one side of the test sample loading hole is pulled out, and the unstained bacterial solution is pumped into the test sample loading hole 6, the drug is pumped into the drug loading hole 5, and the sterile water is pumped into the diluent loading hole 7. In the concentration gradient generator 8, a concentration gradient is automatically formed. The excess unreacted liquid is sucked out from the waste liquid hole 9 of the concentration gradient generator. The concentration gradient generator 8 is of a "Christmas tree" type and includes n (n + 3) / 2 drug sensitivity culture pools, where n is equal to 1, 2, 3, 4... When n = 5, in the last row of six drug sensitivity culture pools in the concentration gradient generator, the drug concentration ratios are 0:1:2:3:4:5 respectively (see the attached figure Figure 4 ). After about 6 hours of culture, the bacteria were tested under different concentrations to obtain the survival of the bacteria after the drug action. The minimum inhibitory concentration (MIC) was determined based on the color depth of the drug sensitivity culture pool, that is, the color intensity (see attached figure). Figure 5 ). The microfluidic chip of the present invention can observe MIC in any column of the concentration gradient generator, which is more convenient and rapid than traditional methods or other microfluidic drug sensitivity test methods.

[0051] Unless otherwise specifically stated, the numerical value set forth in these embodiments does not limit the scope of the present invention. In all examples shown and described here, unless otherwise specified, any specific value should be interpreted as merely exemplary, rather than as restriction, and therefore, other examples of exemplary embodiments may have different values.

[0052] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. These modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention, and they should all be included in the scope of the claims and specification of the present invention.

Claims

1. A microfluidic chip, characterized in that: The microfluidic chip comprises a top layer, a middle layer and a bottom layer, wherein the middle layer is a PDMS structure, the bottom layer is a glass slide, the middle layer comprises four regions: an inlet region, a detection region, a concentration gradient generator and a waste liquid hole, and the inlet region is located between the detection region and the concentration gradient generator, the concentration gradient generator is a "Christmas tree" type, and comprises n(n+3) / 2 drug sensitivity culture pools and a curved channel corresponding to each drug sensitivity culture pool, wherein n is equal to 1, 2, 3, 4...; The waste liquid hole comprises a detection zone waste liquid hole (1) and a concentration gradient generator waste liquid hole (9), wherein the detection zone waste liquid hole (1) is connected to the detection zone via a liquid channel, and the concentration gradient generator waste liquid hole (9) is connected to the downstream of the drug sensitivity culture tank via a liquid channel; A curved channel (10) is provided between the inlet area and the concentration gradient generator and between each drug sensitivity culture pool; the width of the channel between the detection area and the detection area waste liquid hole (1) is 40 μm, and the width of all other channels is 100 μm; the inlet area includes a sample loading hole for the test sample, a diluent / buffer loading hole for drug sensitivity test, and a drug loading hole; the sample loading hole for the test sample is located on one side of the concentration gradient generator and is provided with a detachable PVDF membrane with a thickness of 90-110 μm; the bottom layer of the inlet area is 2-4 μm higher than the bottom layers of other areas; The sample loading hole in the inlet area is connected to the detection area waste liquid hole (1) through the detection area, and the sample loading hole in the inlet area is also connected to the concentration gradient generator waste liquid hole (9) through the concentration generator; The diluent / buffer injection hole and the drug injection hole in the inlet area are connected to the concentration gradient generator waste liquid hole (9) via the concentration generator; The detection zone includes a micro-tray and micro-beads; the micro-beads are prepared antibody-coated micro-beads, and the micro-beads are pumped into the detection zone from the sample injection hole to be tested; The bacterial solution to be tested is added to the detection zone from the sample loading hole to be tested in the inlet zone, so that the bacterial solution to be tested is captured by the microbeads; wherein, during the bacterial solution detection, the PVDF membrane prevents the bacterial solution from flowing into the concentration gradient generator; During the drug sensitivity test, the PVDF membrane of the sample loading hole to be tested, which is located on one side of the concentration gradient generator, is pulled out to form a bacterial liquid flow channel, and flows into the concentration gradient generator; the unstained bacterial liquid is pumped into the sample loading hole to be tested, and the fluorescent reaction of the bacterial liquid in the detection area is positive; the drug is pumped into the drug loading hole, and the diluent / buffer loading hole is pumped into the diluent or sterile water, and a concentration gradient is automatically formed in the concentration gradient generator, and the minimum inhibitory concentration MIC can be observed in any column in the concentration gradient generator; The preparation method of the microfluidic chip comprises: firstly sealing the middle layer of the microfluidic chip with the bottom layer of the microfluidic chip, and then placing sterile filter paper sheets in the drug sensitivity culture tank respectively, and then sealing the middle layer of the microfluidic chip with the top layer of the microfluidic chip after plasma treatment, and each layer of the microfluidic chip is baked at 90°C for 2h before sealing, and irradiated with ultraviolet light overnight.

2. The microfluidic chip according to claim 1, characterized in that: The diameter of the drug sensitivity culture pool is 2-5 mm, and the diameter of the waste liquid hole is 0.5-1 mm.

3. The microfluidic chip according to claim 1, characterized in that: The micro-tray is V-shaped or semicircular, the diameter of the micro-beads is 60-90 μm, and the micro-tray is slightly wider than the micro-beads to hold up the micro-beads.

4. The use of the microfluidic chip according to any one of claims 1 to 3 in pathogen identification and drug sensitivity testing, characterized in that: The method comprises the following steps: Step S1: After each layer of the chip is sterilized by high pressure, the bottom layer is sealed with the middle layer, a culture medium is added to the drug sensitivity culture pool, and then a sterile filter paper is added to the drug sensitivity culture pool, and the upper layer is sealed, and the sealed complete chip is stored in a refrigerator at 4°C, and the chip surface is irradiated with an ultraviolet lamp for 30 minutes before use; Step S2: prepare antibody-coated microbeads, and pump them into the detection area from the sample loading hole to be tested. After the microbeads enter the detection area, they are rinsed and pressurized with PBS to ensure that there is a microbead on each microtray. The bacteria to be tested are added to the detection area from the sample loading hole to be tested in the inlet area so that the bacterial solution is captured by the microbeads. The excess bacterial solution is rinsed with PBS, and the excess bacterial solution is sucked out from the waste liquid hole (1) of the detection area. According to the test bacteria, the corresponding rabbit primary antibody working solution and FITC-labeled goat anti-rabbit fluorescent secondary antibody working solution are added. After the reaction is completed, the excess unreacted liquid is rinsed with PBS, and the excess liquid is sucked out from the waste liquid hole (1) of the detection area. The chip detection area is observed under a fluorescence microscope, and the average fluorescence color concentration of the observation result is analyzed by Image Pro software. According to the standard curve, the concentration of the bacteria to be tested is determined. The whole step is carried out in a portable constant temperature box at 37°C. Step S3: If the fluorescence reaction of the detection area is negative, it proves that the result of the detected bacteria is negative, and the drug sensitivity test is not performed; if the fluorescence reaction of the detection area is positive, the drug sensitivity test is continued.

5. The use according to claim 4, characterized in that The steps of the drug sensitivity test include: step S31: flushing the liquid channel with PBS, pumping the drug into the drug injection hole, pumping the diluent into the diluent / buffer injection hole, forming drugs with different concentration gradients in each column of holes through a concentration gradient generator, and after the sterile filter paper in the drug sensitivity culture pool is completely soaked with the drug, removing the excess drug solution flowing out of the waste liquid hole (9) of the concentration gradient generator; step S32: pulling out the PVDF membrane on one side of the sample injection hole to be tested, and adding the bacterial solution confirmed to contain pathogens in step S2 to the sample injection hole to be tested, after the bacterial solution fills all the drug sensitivity culture pools, removing the excess bacterial solution flowing out of the waste liquid hole (9) of the concentration gradient generator, placing the chip in an incubator for culture, and judging the minimum inhibitory concentration MIC according to the color depth.

6. The use according to claim 5, characterized in that The standard curve in step S2 is drawn by taking 0.5 MCF concentration as equivalent to 1.5×10 8 cfu / mL Escherichia coli was used as a reference, and 1.5×10 8 cfu / mL, 1.5×10 7 cfu / mL, 1.5×10 6 cfu / mL, 1.5×10 5 cfu / mL, 1.5×10 4 cfu / mL, 1.5×10 3 cfu / mL, 1.5×10 2 cfu / mL, 1.5×10 1 Cfu / mL concentration of bacterial solution was added to the detection area respectively. After passing through the detection area, the excess unreacted bacterial solution was washed away and observed using a fluorescence microscope. The observation results were analyzed using Image Pro software to analyze the average fluorescence color concentration and draw a standard curve.

Citation Information

Patent Citations

  • Micro -fluidic chip

    CN206244793U

  • Micro-fluidic chip

    CN210803495U

  • Micro-fluidic chip

    CN210982463U